1 |
<p><b>Researching the Fight Against Infection</b></p> |
2 |
<p>PLIVA's anti-infectives research is being conducted in three separate programs: |
3 |
Macrolide research, New Antibiotics research, and Biodiversity discovery.</p> |
4 |
<p>With its internationally acknowledged insight into macrolide chemistry, as |
5 |
evidenced by its discovery of Azithromycin, PLIVA has entered into a strategic |
6 |
co-operation with GlaxoWellcome (currently <a |
7 |
href="http://www.gsk.com">GlaxoSmithKline</a>) to identify a novel macrolide |
8 |
antibiotic for world-wide development and marketing. The goal of this venture |
9 |
is to identify a macrolide with improved efficacy, particularly against resistant |
10 |
strains of bacteria.</p> |
11 |
<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202" border=1></p> |
12 |
<p>The goal of PLIVA's second program is to find a novel anti-bacterial compound |
13 |
class showing no cross-resistance with current antibiotics. In cooperation with |
14 |
<a href="http://www.althexis.com">Althexis</a>, Boston, USA, a company with |
15 |
leading expertise in |
16 |
structure-based drug |
17 |
design and crystallography, researchers from both companies have identified |
18 |
two novel scaffolds showing activity with <i>in vitro</i> and <i>in vivo</i> |
19 |
models of infections. A derivatization program |
20 |
to identify a developmental candidate within the shortest possible time has |
21 |
been fully established.</p> |
22 |
<p>As an extension of its anti-bacterial program, PLIVA has licensed-in a novel |
23 |
anti-fungal compound (PLD-118) from <a href="http://www.bayer.com">Bayer |
24 |
AG</a>, Germany. This compound has demonstrated |
25 |
excellent efficacy against the most common systemic fungal infections as well |
26 |
as excellent tolerability and pharmacokinetic properties in various pre-clinical |
27 |
models. PLD-118 would represent the first novel, orally available compound class |
28 |
for the treatment of infections caused by the Candida yeast since the introduction |
29 |
of the azoles in the 1970s.The project has a novel mode of action and has strong |
30 |
potential to solve azole resistance problems.</p> |
31 |
<p>In the Biodiversity program, activities are being focused on generating the |
32 |
"toolbox" for the generation of novel enzymes and the application of the technology |
33 |
to streptomyces, one of the most important microbial organisms for the production |
34 |
of small molecules. Significant improvement of the general technology, which |
35 |
is currently patented, has been achieved. The Biodiversity program is conducted |
36 |
in both MIXIS France and PLIVA Zagreb laboratories, and it should give MIXIS |
37 |
a vehicle for future products, a far longer patent protection and simplified |
38 |
and attractive format. </p> |